GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Price-to-Owner-Earnings

Immix Biopharma (Immix Biopharma) Price-to-Owner-Earnings : (As of Jun. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma Price-to-Owner-Earnings?

As of today (2024-06-10), Immix Biopharma's share price is $2.0101. Immix Biopharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Immix Biopharma's Price-to-Owner-Earnings or its related term are showing as below:


IMMX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.2
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-10), Immix Biopharma's share price is $2.0101. Immix Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.93. Therefore, Immix Biopharma's PE Ratio for today is At Loss.

As of today (2024-06-10), Immix Biopharma's share price is $2.0101. Immix Biopharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.93. Therefore, Immix Biopharma's PE Ratio without NRI for today is At Loss.

During the past 5 years, Immix Biopharma's highest PE Ratio without NRI was 160.61. The lowest was 0.00. And the median was 0.00.


Immix Biopharma Price-to-Owner-Earnings Historical Data

The historical data trend for Immix Biopharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Price-to-Owner-Earnings Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Immix Biopharma Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immix Biopharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Immix Biopharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immix Biopharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's Price-to-Owner-Earnings falls into.



Immix Biopharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Immix Biopharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.0101/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immix Biopharma  (NAS:IMMX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Immix Biopharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Immix Biopharma (Immix Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.
Executives
Jason Hsu director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Helen C. Adams director 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan director 1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky director, 10 percent owner C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Ilya M Rachman director, officer: CEO and Chairman 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris director, officer: Chief Financial Officer 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Sean Senn 10 percent owner 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin officer: Scientific Co-Founder 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross officer: CMO & Head of Clinical Dev. 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064

Immix Biopharma (Immix Biopharma) Headlines

From GuruFocus